

Targeting RET in Patients With *RET*-Rearranged Lung Cancers: Results From the Global, Multicenter *RET* Registry

Oliver Gautschi, Julie Milia, Thomas Filleron, Juergen Wolf, David P. Carbone, Dwight Owen, Ross Camidge, Vignesh Narayanan, Robert C. Doebele, Benjamin Besse, Jordi Remon-Masip, Pasi A. Janne, Mark M. Awad, Nir Peled, Chul-Cho Byoung, Daniel D. Karp, Michael Van Den Heuvel, Heather A. Wakelee, Joel W. Neal, Tony S.K. Mok, James C.H. Yang, Sai-Hong Ignatius Ou, Georg Pall, Patrizia Froesch, Gérard Zalcman, David R. Gandara, Jonathan W. Riess, Vamsidhar Velcheti, Kristin Zeidler, Joachim Diebold, Martin Friih, Sebastian Michels, Isabelle Monnet, Sanjay Papat, Rafael Rosell, Niki Karachaliou, Sacha I. Rothschild, Jin-Yuan Shih, Arne Warth, Thomas Muley, Florian Cabillic, Julien Mazières, and Alexander Drilon

Author affiliations and support information (if applicable) appear at the end of this article.

Published at jco.org on March 13, 2017.

Corresponding author: Oliver Gautschi, MD, Medical Oncology, Cantonal Hospital Luzern, Spitalstrasse 10, 6000 Luzern, Switzerland; e-mail: oliver.gautschi@luks.ch.

© 2017 by American Society of Clinical Oncology

0732-183X/17/3513w-1403w/\$20.00

A B S T R A C T

Purpose

In addition to prospective trials for non–small-cell lung cancers (NSCLCs) that are driven by less common genomic alterations, registries provide complementary information on patient response to targeted therapies. Here, we present the results of an international registry of patients with *RET*-rearranged NSCLCs, providing the largest data set, to our knowledge, on outcomes of *RET*-directed therapy thus far.

Methods

A global, multicenter network of thoracic oncologists identified patients with pathologically confirmed NSCLC that harbored a *RET* rearrangement. Molecular profiling was performed locally by reverse transcriptase polymerase chain reaction, fluorescence in situ hybridization, or next-generation sequencing. Anonymized data—clinical, pathologic, and molecular features—were collected centrally and analyzed by an independent statistician. Best response to *RET* tyrosine kinase inhibition administered outside of a clinical trial was determined by RECIST v1.1.

Results

By April 2016, 165 patients with *RET*-rearranged NSCLC from 29 centers across Europe, Asia, and the United States were accrued. Median age was 61 years (range, 29 to 89 years). The majority of patients were never smokers (63%) with lung adenocarcinomas (98%) and advanced disease (91%). The most frequent rearrangement was *KIF5B-RET* (72%). Of those patients, 53 received one or more *RET* tyrosine kinase inhibitors in sequence: cabozantinib (21 patients), vandetanib (11 patients), sunitinib (10 patients), sorafenib (two patients), alectinib (two patients), lenvatinib (two patients), nintedanib (two patients), ponatinib (two patients), and regorafenib (one patient). The rate of any complete or partial response to cabozantinib, vandetanib, and sunitinib was 37%, 18%, and 22%, respectively. Further responses were observed with lenvatinib and nintedanib. Median progression-free survival was 2.3 months (95% CI, 1.6 to 5.0 months), and median overall survival was 6.8 months (95% CI, 3.9 to 14.3 months).

Conclusion

Available multikinase inhibitors had limited activity in patients with *RET*-rearranged NSCLC in this retrospective study. Further investigation of the biology of *RET*-rearranged lung cancers and identification of new targeted therapeutics will be required to improve outcomes for these patients.

J Clin Oncol 35:1403-1410. © 2017 by American Society of Clinical Oncology

INTRODUCTION

The use of targeted therapy is a standard of care for subgroups of patients with advanced non–small-cell lung cancer (NSCLC), including those whose tumors harbor sensitizing *EGFR* mutations

and *ALK* or *ROS1* rearrangements.¹ As the molecular landscape of NSCLC unfolds—largely secondary to improvements in comprehensive molecular profiling—rare but clinically actionable drivers continue to emerge.² For less common driver mutations, it has become increasingly difficult to mount and complete prospective trials

within a time frame that generates data that help guide clinical decisions.

To complement ongoing prospective investigations, cohort studies generated by multicenter registries provide information on clinicopathologic and molecular features as well as outcomes with targeted therapy,³ as evidenced by works we previously published for patients with *ROS1*-rearranged, *BRAF*-mutant, and *ERBB2*-mutant lung cancers.⁴⁻⁷ Our registries demonstrate that clinicians are inclined to test for less common genomic alterations and to treat patients whose tumors harbor these drivers.

The rearranged during transfection, or *RET* gene, is a known proto-oncogene.⁸⁻¹¹ Oncogenic activation can occur via mutation or rearrangement. *RET* rearrangement was first detected in NIH-3T3 cells that were transfected with lymphoma DNA¹² and subsequently identified in papillary thyroid cancers.^{13,14} In NSCLCs, *RET* rearrangements occur in 1% to 2% of unselected cases. These are commonly found in adenocarcinomas from patients who are never smokers or who have minimal history of tobacco exposure.¹⁵ In contrast to thyroid cancer where *CCDC6* and *NCOA4* are more common upstream partner genes, *KIF5B* is the most common upstream fusion partner of *RET* in NSCLC.¹⁶⁻²¹

Independent investigators have demonstrated that multi-kinase *RET* inhibitors, such as cabozantinib and vandetanib, are active in vitro and in vivo against various *RET*-rearranged lung cancer models.²²⁻²⁴ Furthermore, Drilon et al²⁵ previously reported the activity of cabozantinib in patients with *RET*-rearranged lung cancers in a phase II trial. Subsequent data on the activity of vandetanib on two separate molecularly enriched phase II trials have likewise been published.^{26,27}

On the basis of these results as well as inclusion of some of these data in the National Comprehensive Cancer Center Network guidelines, clinicians who practice in a variety of settings have treated patients with *RET*-rearranged lung cancer outside the context of a clinical trial with different *RET* inhibitors.²⁸⁻³³ These therapies include cabozantinib, vandetanib, sorafenib, and levatinib, which are approved for treatment of advanced thyroid cancers, and ponatinib, alectinib, and sunitinib, which are approved for other indications.

We set out to systemically gather and analyze these data by launching the Global, Multicenter *RET* Registry (GLORY) in 2015. In this article, we present the results of this collective experience with a focus on outcomes with multi-kinase *RET* inhibitor therapy in patients with *RET*-rearranged lung cancers.

METHODS

Study Objectives

The aims of this study were to describe the clinicopathologic characteristics of patients with *RET*-rearranged lung cancers and to document the outcomes of patients with advanced disease who were treated with systemic therapy, focusing on multi-kinase inhibitors that target the *RET* kinase.

Patient Selection

A global, multicenter network of thoracic oncologists accrued patients with *RET*-rearranged lung cancers to this registry. Investigators were identified via ongoing collaboration that was established by our prior registry efforts in other subsets of driver-positive lung cancer.⁴⁻⁷ Eligible

patients had a pathologic diagnosis of NSCLC of any stage (I to IV) and *RET* rearrangement by a validated test that was performed in an accredited local laboratory. Accepted test methods were fluorescence in situ hybridization, reverse transcriptase polymerase chain reaction, and next-generation sequencing. Validation of test results by a second method was not mandatory. Investigators administered multi-kinase inhibitors cabozantinib, vandetanib, sunitinib, sorafenib, alectinib, levatinib, nintedanib, ponatinib, and regorafenib according to the approved initial starting dose of these drugs in their respective approved cancer indications—data on dose interruption and modification were not collected. Participating centers were responsible for patient consent and institutional approval. All contributors were trained in good clinical practice. The study was purely an academic collaboration and was not funded by industry.

Data Collection and Response Assessment

Anonymized clinical data—age, gender, *RET* upstream fusion partner, tumor stage, date of diagnosis, initiation and completion of *RET* inhibitor therapy, progression, and death—were recorded. Anonymous data were collected centrally at the University of Toulouse. The registry was opened in June 2015 and data cutoff was on April 15, 2016. Patients who were treated with a *RET* inhibitor outside of the context of a clinical trial were eligible for analysis of efficacy of *RET* inhibitor therapy. *RET* inhibitor therapy was defined as treatment with any drug that is known to inhibit *RET* kinase at clinically relevant concentrations.³⁴⁻³⁷ Best response to systemic therapies, defined as a complete or partial response achieved at least once during the course of therapy, was assessed locally by each investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).³⁸ As a result of the limits of this registry and the lack of a formal response assessment plan for each patient, response confirmation could not be assessed and overall response rate could not be calculated. Patients who were treated with *RET* inhibitor therapy in a clinical trial were not included in an analysis of efficacy of *RET* inhibitor therapy.

Statistical Methods

Data were summarized according to frequency and percentage for qualitative variables as well as by medians and ranges for quantitative variables. Comparisons between groups were performed by using the χ^2 test or Fisher's exact test for qualitative variable test, and by the Mann-Whitney test for quantitative variables. Progression-free survival was measured as the time from the first administration of *RET* inhibitor therapy to progression defined by RECIST v1.1 or death from any cause. Patients who were alive without having experienced progression at the time of analysis were censored at their last follow-up. Overall survival was measured as the time from the first administration of *RET* inhibitor therapy to death from any cause. Patients who were alive at the time of analysis were censored at their last follow-up. Survival rates were estimated by using the Kaplan-Meier method. Statistical analyses were carried out by using STATA software (version 13.0; STATA, College Station, TX; Computing Resource Center, Santa Monica, CA).

RESULTS

Clinicopathologic and Molecular Features

From June 2015 to April 2016, 29 different centers from 12 countries in Europe, Asia, and the United States contributed a total of 165 patients (Table 1). Median age was 61 years (range, 29 to 89 years) and the percentage of males and females was balanced. The majority of patients (103 of 165 patients; 63%) were never smokers. Lung adenocarcinoma was the predominant histology (158 of 162 patients; 98%). Most patients (117 of 165 patients; 72%) had stage IV disease at diagnosis. Molecular testing for *RET* was performed locally via fluorescence in situ hybridization,

Table 1. Clinicopathologic Features

Characteristic	All Patients (N = 165)	Patients not Treated With a <i>RET</i> Inhibitor (n = 112)	Patients Treated With a <i>RET</i> Inhibitor (n = 53)	<i>P</i> *
Age, years				.166
Median (range)	61 (28-89)	62 (29-89)	57 (28-83)	
< 70	126 (76)	82 (79)	44 (83)	
≥ 70	39 (24)	30 (27)	9 (17)	
Gender				.260
Male	79 (48)	57 (51)	22 (42)	
Female	86 (52)	55 (49)	31 (59)	
Smoking history				.110
Never	103 (63)	69 (62)	34 (65)	
Former	45 (27)	35 (31)	10 (19)	
Current	16 (10)	8 (7)	8 (15)	
Unknown	1	0	1	
Tumor histology				.487
Adenocarcinoma	158 (98)	108 (98)	50 (96)	
Squamous	1 (1)	0	1 (2)	
NSCLC NOS	3 (2)	2 (2)	1 (2)	
Unknown	3	2	1	
<i>RET</i> fusion gene partner				.327
<i>KIF5B</i>	58 (72)	39 (68)	19 (79)	
Other	23 (28)	18 (32)	5 (21)	
Unknown	84	55	29	
Stage at diagnosis				.004
I and II	14 (9)	14 (13)	0	
III	31 (19)	24 (22)	7 (14)	
IV	117 (72)	73 (66)	44 (86)	
Unknown	3	1	2	
Region				.3103
United States	68 (41.2)	48 (42.9)	20 (37.7)	
Europe and Israel	71 (43.0)	44 (39.3)	27 (50.9)	
Asia	26 (15.8)	20 (17.9)	6 (11.3)	

NOTE. Data are given as No. (%) unless otherwise noted. Clinicopathologic features of 165 patients with *RET*-rearranged lung cancers are summarized. In addition, the clinicopathologic features of 53 patients with advanced *RET*-rearranged lung cancers who received a *RET* inhibitor during the course of treatment are summarized and compared with 112 patients who did not receive a *RET* inhibitor.

Abbreviations: NOS, not otherwise specified; NSCLC, non-small-cell lung cancer.

*Fisher's exact and χ^2 tests

next-generation sequencing, and real-time polymerase chain reaction. Upstream fusion partners were identified in 81 tumor samples. *KIF5B* was the most common partner and was found in 58 patients (72%), followed by *CCDC6* in 19 patients (23%), *NCOA4* in two patients (2%), *EPHA5* in one patient (1%), and *PICALM* in one patient (1%).

Outcomes With *RET* Inhibitor Therapy in Tyrosine Kinase Inhibitor–Naïve Patients

Fifty-three tyrosine kinase inhibitor (TKI)–naïve patients with *RET*-rearranged lung cancers received a *RET* inhibitor during the course of therapy. All patients had advanced (stage III and IV) disease. Apart from stage, clinical characteristics did not differ from patients who were not treated with a *RET* inhibitor (Table 1). All patients received their first *RET* inhibitor as a single agent. TKIs administered included cabozantinib in 21 patients, vandetanib in 11 patients, sunitinib in 10 patients, sorafenib in two patients, alectinib in two patients, lenvatinib in two patients, nintedanib in two patients, ponatinib in two patients, and regorafenib in one patient. The median line of systemic therapy of the first *RET* TKI administered was as third line (range, first to eighth line). Median time from initial diagnosis to the start of *RET* inhibitor therapy was 12.0 months (range, 0.1 to 92.0 months).

Of 53 patients, data on response to therapy by RECIST v1.1 was available in 50 patients. The best response to single-agent *RET* inhibition of any kind was complete response in two patients (4%), partial response in 11 patients (22%), stable disease in 16 patients (32%), progressive disease in 20 patients (40%), and not evaluable in one patient (2%). Responses were observed with cabozantinib, vandetanib, sunitinib, lenvatinib, and nintedanib, but not with sorafenib, alectinib, ponatinib, or regorafenib (Table 2). There were no statistically significant differences in terms of best response and progression-free or overall survival with *RET* inhibitor therapy by upstream fusion partner (*KIF5B* v other partner) in 24 patients in whom the gene partner was known. Response to therapy was noted in three patients with non-*KIF5B* fusion partners, including two with *CCDC6-RET* and one with *EPHA5-RET*.

A swimmer's plot outlining the duration of *RET* inhibitor therapy for each of the 53 patients is shown in Fig 1. Median duration of *RET* inhibitor therapy was 1.8 months (range, 0.5 to 12 months). At the data cutoff, eight patients (15%) remained on *RET* inhibitor therapy, and 45 patients (85%) had discontinued treatment. Median progression-free survival was 2.3 months (95% CI, 1.6 to 5.0 months). Twenty-one patients (40%) were alive at the time of the analysis. Median overall survival was 6.8 months (95% CI, 3.9 to 14.3 months). Kaplan-Meier survival curves are shown in Fig 2.

Table 2. Best Response to RET Inhibitor Therapy

RET Inhibitor	Complete Response	Partial Response	Stable Disease	Disease Progression	Not Evaluable	Missing Data
All agents (n = 53)	2 (4%)	11 (22%)	16 (32%)	20 (40%)	1 (2%)	3
Cabozantinib (n = 21)	1 (5%)	6 (32%)	5 (26%)	7 (37%)	0	2
Vandetanib (n = 11)	0	2 (18%)	3 (27%)	6 (55%)	0	0
Sunitinib (n = 10)	0	2 (22%)	3 (33%)	3 (33%)	1 (11%)	1
Sorafenib (n = 2)	0	0	2	0	0	0
Alectinib (n = 2)	0	0	0	2	0	0
Lenvatinib (n = 2)	0	1	0	1	0	0
Nintedanib (n = 2)	1	0	1	0	0	0
Ponatinib (n = 2)	0	0	2	0	0	0
Regorafenib (n = 1)	0	0	0	1	0	0

NOTE. The best response to a multikinase inhibitor with activity against RET is summarized for 53 patients with advanced *RET*-rearranged lung cancers.

Outcomes With Specific RET Inhibitors in TKI-Naïve Patients

Analysis of the efficacy of individual RET TKIs was performed if each drug was administered to at least 10 RET TKI-naïve patients with *RET*-rearranged NSCLC (Table 3). The best response to cabozantinib was complete response in one patient (5%), partial response in six patients (32%), stable disease in five patients (26%), and disease progression in seven patients (37%). Median progression-free survival was 3.6 months (95% CI, 1.3 to 7.0 months) and median overall survival was 4.9 months (95% CI, 1.9 to 14.3 months).

The best response to vandetanib was partial response in two patients (18%), stable disease in three patients (27%), and disease progression in six patients (55%). No complete responses were observed. Median progression-free survival was 2.9 months (95% CI, 1.0 to 6.4 months) and median overall survival was 10.2 months (95% CI, 2.4 months to not reached).

The best response to sunitinib was partial response in two patients (22%), stable disease in three patients (33%), disease progression in three patients (33%), and not evaluable in one patient (11%). No complete responses were observed. Median

progression-free survival was 2.2 months (95% CI, 0.7 to 5.0 months) and median overall survival was 6.8 months (95% CI, 1.1 months to not reached).

Outcomes With Sequential RET Inhibitor Therapy

Of 53 patients who received a RET inhibitor during the course of their disease, 43 patients received only one RET inhibitor. The remaining 10 patients received two or more RET inhibitors sequentially: eight patients received two RET inhibitors in sequence, and two patients received three RET inhibitors in sequence. In three patients, a partial response to a RET inhibitor was observed after prior treatment with a different RET inhibitor.

Outcomes With Chemotherapy

Eighty-four patients with advanced disease at initial diagnosis and *RET*-rearranged lung cancers received platinum-based chemotherapy in the first-line setting (Table 4). In these patients, a best response of complete or partial response was achieved in 33 (51%; 95% CI, 38.1 to 63.4) of 65 response-evaluable patients. Median progression-free survival was 7.8 months (95% CI, 5.3 to 10.2 months) and median overall survival was 24.8 months (95% CI, 13.6 to 32.3 months) in 70 patients with survival data.

Of 84 patients who received a platinum doublet in the first-line setting, 66 patients received a platinum agent and pemetrexed. In these patients, a best response of complete or partial response was achieved in 27 (49%; 95% CI, 35.4 to 62.9) of 55 response-evaluable patients. Median progression-free survival was 6.4 months (95% CI, 4.3 to 8.8 months) and median overall survival was 23.6 months (95% CI, 13.4 to 33.2 months) in 57 patients with survival data.




Fig 1. Duration of RET inhibitor therapy in RET tyrosine kinase inhibitor (TKI)-naïve patients. Duration of multikinase inhibitor therapy with activity against RET is shown for 53 RET TKI-naïve patients with advanced *RET*-rearranged lung cancers. Solid lines represent duration of TKI therapy, arrows represent ongoing therapy, and diamonds represent tumor progression.

DISCUSSION

To the best of our knowledge, GLORY represents the largest single database of patients with *RET*-rearranged lung cancers. This global, multicenter registry was organized independently of industry support, and with limited academic resources, generated meaningful clinical data within a short time period. The number of contributions and participating centers exceeded our expectations, which demonstrated the interest of the community in less common driver mutations as well as the feasibility of international academic




Fig 2. Survival with *RET* inhibitor therapy. (A and B) Kaplan-Meier curves of progression-free survival (PFS) are shown for patients with *RET*-rearranged lung cancers who received (A) any multikinase inhibitor with activity against *RET*, and (B) cabozantinib, vandetanib, or sunitinib. (C and D) Kaplan-Meier curves of overall survival (OS) are shown for patients with *RET*-rearranged lung cancers who received (C) any multikinase inhibitor with activity against *RET* and (D) cabozantinib, vandetanib, or sunitinib.

projects of this nature. Whereas our study has several limitations, including reporting bias, lack of central molecular and radiologic assessment, variable scanning intervals, and the inability to analyze dose modifications and interruptions, we were able to confirm the results of independent retrospective and prospective series that described clinicopathologic features of *RET*-rearranged lung cancers and collected real-world data on the use of *RET*-directed, targeted therapy outside of clinical protocols.

Our data are consistent with previous studies that have shown that *RET* rearrangements are identified predominantly in adenocarcinomas from patients with a minimal to no history of tobacco exposure. In our registry, *RET* rearrangements were also identified, albeit at a lower frequency, in smokers and in patients with NSCLCs not otherwise specified. Future efforts should focus on systematically assessing potential risk factors for the development

of *RET* rearrangement in NSCLC, including radiation and occupational exposures.³⁹

Whereas overall outcomes were disappointing compared with the activity of targeted therapy in other genomic subsets of lung cancer, we observed that multikinase *RET* inhibitors induced sustained responses in a subset of patients with *RET*-rearranged lung cancers. Whereas nine *RET* inhibitors were used in this registry, which provided a unique opportunity to explore the clinical activity of different agents, these results must be interpreted with caution. Although our registry was retrospective and drug dosage was not controlled, the activity of cabozantinib in our series was comparable to that reported for an ongoing phase II clinical trial of the drug in *RET*-rearranged lung cancers (n = 26; overall response rate [ORR], 28%; median progression-free survival [PFS], 5.5 months).⁴⁰ Likewise, the activity of vandetanib in our

Table 3. Clinical Outcomes With Specific Multikinase RET Inhibitors

RET Inhibitor	Best Response (%; 95% CI)	Median DoT (range)	Median PFS (95% CI)	Median OS (95% CI)
Cabozantinib	7 of 19 evaluable (37%; 16.3 to 61.6)	1.6 months (0.5 to 12.2 months)	3.6 months (1.3 to 7.0 months)	4.9 months (1.9 to 14.3 months)
Vandetanib	2 of 11 evaluable (18%; 2.3 to 51.8)	2.9 months (0.8 to 7.1 months)	2.9 months (1.0 to 6.4 months)	10.2 months (2.4 months to NR)
Sunitinib	2 of 9 evaluable (22%; 2.8 to 60.0)	2.2 months (0.7 to 6.6 months)	2.2 months (0.7 to 5.0 months)	6.8 months (1.1 months to NR)

NOTE. The percentage of patients who achieved a complete or partial response as their best response, and the median DoT, median PFS, and median OS with cabozantinib, vandetanib, and sunitinib are summarized.

Abbreviations: DoT, duration of treatment; NR, not reached; OS, overall survival; PFS, progression-free survival.

series was comparable to results of an ongoing phase II trial of the drug in Korean patients ($n = 19$; ORR, 18%; median PFS, 4.5 months), but less than that observed in a separate phase II trial of the same drug in Japanese patients ($n = 19$; ORR, 53%; median PFS, 4.7 months).^{26,27} The reasons for discrepant response rates between the latter two trials remains unclear. More recently, preliminary results of a trial with lenvatinib were presented ($n = 25$; ORR, 16%; median PFS, 7.3 months).⁴¹

Whereas the activity of *RET* inhibition is documented in some patients with *RET*-rearranged lung cancers, and the ORR exceeds the historical response rate of single-agent chemotherapy in this setting ($< 10\%$ with docetaxel in the second-line setting), it is important to point out that the activity of these drugs is markedly lower than that observed with targeted therapy in *EGFR*-mutant and *ALK/ROS1*-rearranged lung cancers. A number of factors may be responsible for this difference. It is possible that inhibition of the *RET* kinase is suboptimal at clinically deliverable doses. Currently available *RET* inhibitors target a variety of kinases, some of which, like *VEGFR2*, are inhibited much more potently than *RET* and result in toxicities that may limit chronic dosing.⁴² In this respect, we look forward to the introduction of highly selective *RET* inhibitors in the clinic. These drugs are likely to result in more potent inhibition of *RET* and less off-target toxicities. Combination therapy represents a second approach to maximizing efficacy, although the potential for increased toxicity will have to be taken into account.⁴³

Other explanations for the relatively low activity of multi-kinase inhibitors include molecular heterogeneity and the presence of concomitant alterations. It has been speculated that the type of fusion partner (*KIF5B* *v* *CCDC6* *v* other partners) may play a role in determining response to treatment.²⁷ In our exploratory analysis of response and survival by fusion type, no statistically significant differences in clinical outcomes were observed. *RET*-rearranged lung cancers may also harbor concurrent genomic alterations that decrease the likelihood of response to therapy.

Given the combined results of our series where a limited number of patients derived meaningful clinical benefit from multikinase inhibition, the published prospective clinical trial data on outcomes with targeted therapy in *RET*-rearranged lung cancers, and the emerging strategies for this genomic subset of patients, our personal preference is to screen for *RET* rearrangements in patients with advanced nonsquamous NSCLC whenever possible. Doing so will allow patients to be enrolled in prospective trials of novel strategies for *RET*-rearranged lung cancers, with the intent of eventually improving outcomes for these patients.

Finally, we demonstrate that *RET*-rearranged lung cancers seem to be sensitive to platinum-based chemotherapy. Given the low activity of currently available multikinase inhibitors, a possible treatment strategy for patients with *RET*-rearranged lung cancer would be to begin first-line chemotherapy and, outside the confines of a clinical trial, to consider a *RET* TKI as a second line of therapy; however, as mentioned above, enrollment of patients in clinical trials of novel targeted therapy strategies is encouraged. Whereas one previous series described the potential sensitivity of *RET*-rearranged lung cancers to pemetrexed-based chemotherapy, the activity of pemetrexed could not be validated in our registry and requires additional work.⁴⁴ The potential efficacy of programmed death-ligand 1 (PD-L1) checkpoint inhibitors in this population has not been tested thus far. Whereas PD-L1 expression was found in *RET*-rearranged lung cancers, the sequencing of *RET* inhibitors and PD-L1 checkpoint inhibitors in patients remains to be established.⁴⁵

RET rearrangement remains a challenging target, and the biology behind these drivers in lung cancer will require further exploration. Despite its many limitations, systemically examining the activity of multikinase inhibitors with activity against *RET* has led to progress over the last few years and created options for patients whose tumors harbor these targets. To conduct prospective trials with larger sample sizes, collaboration between various investigators and centers around the globe will be crucial. As a means of

Table 4. Clinical Outcomes With First-Line Chemotherapy

Outcome	All Chemotherapy Agents (n = 108)	Platinum Doublet (n = 84)	Platinum + Pemetrexed (n = 66)
Best response (95% CI)	52% (39.8 to 64.4) 36 of 69 evaluable	51% (38.1 to 63.4) 33 of 65 evaluable	49% (35.4 to 62.9) 27 of 55 evaluable
Disease control rate (95% CI)	75% (63.5 to 84.9) 52 of 69 evaluable	75% (63.1 to 85.2) 49 of 65 evaluable	75% (61.0 to 85.3) 41 of 55 evaluable
Median PFS (95% CI)	6.6 months (5.1 to 9.3)	7.8 months (5.3 to 10.2 months)	6.4 months (4.3 to 8.8 months)
Median OS (95% CI)	23.6 months (13.6 to 30.8)	24.8 months (13.6 to 32.3 months)	23.6 months (13.4 to 33.2 months)

NOTE. The best response, disease control rate, median PFS, and median OS of patients with advanced non-small-cell lung cancer and first-line chemotherapy are summarized.

Abbreviations: OS, overall survival; PFS, progression-free survival.

complementing these efforts, international academic registries, such as GLORY, that explore the efficacy of systemic therapies in real-world settings can generate meaningful results and networks.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at jco.org.

AUTHOR CONTRIBUTIONS

Conception and design: Oliver Gautschi, Julie Milia, Juergen Wolf, Julien Mazières, Alexander Drilon

Financial support: Julien Mazières

Administrative support: Oliver Gautschi, Julie Milia, Thomas Filleron, Julien Mazières

Provision of study materials or patients: Oliver Gautschi, Julie Milia, Juergen Wolf, David P. Carbone, Dwight Owen, Ross Camidge, Vignesh Narayanan, Robert C. Doebele, Benjamin Besse, Jordi Remon-Masip, Pasi A. Janne, Mark M. Awad, Nir Peled, Byoung-Chul Cho, Daniel D. Karp,

Michel Van Den Heuvel, Heather A. Wakelee, Joel W. Neal, Tony S.K. Mok, James C.H. Yang, Sai-Hong Ignatius Ou, Georg Pall, Patrizia Froesch, Gérard Zalcman, David R. Gandara, Jonathan W. Riess, Vamsidhar Velcheti, Kristin Zeidler, Joachim Diebold, Martin Früh, Sebastian Michels, Isabelle Monnet, Sanjay Papat, Rafael Rosell, Niki Karachaliou, Sacha I. Rothschild, Jin-Yuan Shih, Arne Warth, Thomas Muley, Julien Mazières, Alexander Drilon

Collection and assembly of data: Oliver Gautschi, Julie Milia, Juergen Wolf, David P. Carbone, Dwight Owen, Ross Camidge, Vignesh Narayanan, Robert C. Doebele, Benjamin Besse, Jordi Remon-Masip, Pasi A. Janne, Mark M. Awad, Nir Peled, Byoung-Chul Cho, Daniel D. Karp, Michel Van Den Heuvel, Heather A. Wakelee, Joel W. Neal, Tony S.K. Mok, James C.H. Yang, Sai-Hong Ignatius Ou, Georg Pall, Patrizia Froesch, Gérard Zalcman, Jonathan W. Riess, Vamsidhar Velcheti, Kristin Zeidler, Joachim Diebold, Martin Früh, Sebastian Michels, Isabelle Monnet, Sanjay Papat, Rafael Rosell, Niki Karachaliou, Sacha I. Rothschild, Jin-Yuan Shih, Arne Warth, Thomas Muley, Florian Cabillic, Julien Mazières, Alexander Drilon

Data analysis and interpretation: Oliver Gautschi, Julie Milia, Thomas Filleron, Juergen Wolf, David R. Gandara, Florian Cabillic, Julien Mazières, Alexander Drilon

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

REFERENCES

- Masters GA, Temin S, Azzoli CG, et al: Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 33:3488-3515, 2015
- Swanton C, Govindan R: Clinical implications of genomic discoveries in lung cancer. *N Engl J Med* 374:1864-1873, 2016
- Hunter DJ, D'Agostino RB Sr: Let's not put all our eggs in one basket. *N Engl J Med* 373:691-693, 2015
- Mazières J, Peters S, Lepage B, et al: Lung cancer that harbors an HER2 mutation: Epidemiologic characteristics and therapeutic perspectives. *J Clin Oncol* 31:1997-2003, 2013
- Mazières J, Zalcman G, Crinò L, et al: Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: Results from the EUROS1 cohort. *J Clin Oncol* 33:992-999, 2015
- Gautschi O, Milia J, Cabarrou B, et al: Targeted therapy for patients with BRAF-mutant lung cancer: Results from the European EURAF cohort. *J Thorac Oncol* 10:1451-1457, 2015
- Mazières J, Barlesi F, Filleron T, et al: Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: Results from the European EUHER2 cohort. *Ann Oncol* 27:281-286, 2016
- Ishizaka Y, Itoh F, Tahira T, et al: Human ret proto-oncogene mapped to chromosome 10q11.2. *Oncogene* 4:1519-1521, 1989
- Schuchardt A, D'Agati V, Larsson-Blomberg L, et al: Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. *Nature* 367:380-383, 1994
- Andrew SD, Capes-Davis A, Delhanty PJ, et al: Transcriptional repression of the RET proto-oncogene by a mitogen activated protein kinase-dependent signalling pathway. *Gene* 298:9-19, 2002
- Arighi E, Borrello MG, Sariola H: RET tyrosine kinase signaling in development and cancer. *Cytokine Growth Factor Rev* 16:441-467, 2005
- Takahashi M, Ritz J, Cooper GM: Activation of a novel human transforming gene, ret, by DNA rearrangement. *Cell* 42:581-588, 1985
- Nikiforova MN, Stringer JR, Blough R, et al: Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. *Science* 290:138-141, 2000
- Romei C, Ciampi R, Elisei R: A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. *Nat Rev Endocrinol* 12:192-202, 2016
- Wang R, Hu H, Pan Y, et al: RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. *J Clin Oncol* 30:4352-4359, 2012
- Richardson DS, Gujral TS, Peng S, et al: Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins. *Cancer Res* 69:4861-4869, 2009
- Saito M, Ishigame T, Tsuta K, et al: A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis. *Carcinogenesis* 35:2452-2456, 2014
- Li F, Feng Y, Fang R, et al: Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. *Cell Res* 22:928-931, 2012
- Cai W, Su C, Li X, et al: KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. *Cancer* 119:1486-1494, 2013
- Matsubara D, Kanai Y, Ishikawa S, et al: Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. *J Thorac Oncol* 7:1872-1876, 2012
- Lee MS, Kim RN, I H, et al: Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma. *Oncotarget* 7:36101-36114, 2016
- Kohno T, Ichikawa H, Totoki Y, et al: KIF5B-RET fusions in lung adenocarcinoma. *Nat Med* 18:375-377, 2012
- Takeuchi K, Soda M, Togashi Y, et al: RET, ROS1 and ALK fusions in lung cancer. *Nat Med* 18:378-381, 2012
- Lipson D, Capelletti M, Yelensky R, et al: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. *Nat Med* 18:382-384, 2012
- Drilon A, Wang L, Hasanovic A, et al: Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. *Cancer Discov* 3:630-635, 2013
- Lee SH, Lee JK, Ahn MJ, et al: Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: A phase II clinical trial. *Ann Oncol pii:mdw559*, 2016
- Yoh K, Seto T, Satouchi M, et al: Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): An open-label, multicentre phase 2 trial. *Lancet Respir Med* 5:42-50, 2017
- Gautschi O, Zander T, Keller FA, et al: A patient with lung adenocarcinoma and RET fusion treated with vandetanib. *J Thorac Oncol* 8:e43-e44, 2013
- Mukhopadhyay S, Pennell NA, Ali SM, et al: RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib. *J Thorac Oncol* 9:1714-1719, 2014
- Falchook GS, Ordóñez NG, Bastida CC, et al: Effect of the RET inhibitor vandetanib in a patient with RET fusion-positive metastatic non-small-cell lung cancer. *J Clin Oncol* 34:e141-e144, 2016
- Michels S, Scheel AH, Scheffler M, et al: Clinicopathological characteristics of RET rearranged lung cancer in European patients. *J Thorac Oncol* 11:122-127, 2016
- Takeda M, Sakai K, Okamoto K, et al: Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity. *Ann Oncol* 27:748-750, 2016
- Lin JJ, Kennedy E, Sequist LV, et al: Clinical activity of alectinib in advanced RET-rearranged non-small cell lung cancer. *J Thorac Oncol* 11:2027-2032, 2016
- Kim DW, Jo YS, Jung HS, et al: An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid

oncogenic RET/papillary thyroid cancer kinases. *J Clin Endocrinol Metab* 91:4070-4076, 2006

35. Wilhelm SM, Dumas J, Adnane L, et al: Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical anti-tumor activity. *Int J Cancer* 129:245-255, 2011

36. Kodama T, Tsukaguchi T, Satoh Y, et al: Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. *Mol Cancer Ther* 13:2910-2918, 2014

37. Mulligan LM: RET revisited: Expanding the oncogenic portfolio. *Nat Rev Cancer* 14:173-186, 2014

38. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours:

Revised RECIST guideline (version 1.1). *Eur J Cancer* 45:228-247, 2009

39. Dacic S, Luvison A, Evdokimova V, et al: RET rearrangements in lung adenocarcinoma and radiation. *J Thorac Oncol* 9:118-120, 2014

40. Drilon A, Rekhtman N, Arcila M, et al: Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: An open-label, single-centre, phase 2, single-arm trial. *Lancet Oncol* 17:1653-1660, 2016

41. Velcheti V., Hida T., Reckamp K.L., et al: Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung. *Ann Oncol* 27:1204PD, 2016 (suppl 6)

42. Yakes FM, Chen J, Tan J, et al: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor,

simultaneously suppresses metastasis, angiogenesis, and tumor growth. *Mol Cancer Ther* 10:2298-2308, 2011

43. Cascone T, Hess KR, Piha-Paul SA, et al: Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors. *J Clin Oncol* 34, 2016 (abstr 9073)

44. Drilon A, Bergagnini I, Delasos L, et al: Clinical outcomes with pemtred-based systemic therapies in RET-rearranged lung cancers. *Ann Oncol* 27:1286-1291, 2016

45. Song Z, Yu X, Cheng G, et al: Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. *J Transl Med* 14:188, 2016

Affiliations

Oliver Gautschi, **Kristin Zeidler**, and **Joachim Diebold**, Lucerne Cantonal Hospital, Luzern; **Patrizia Froesch**, Ente Ospedaliero Cantonale, Bellinzona; **Martin Früh**, Kantonsspital St Gallen, St Gallen; **Sacha I. Rothschild**, University Hospital Basel, Basel, Switzerland; **Julie Milia** and **Julien Mazières**, Hôpital Larrey; **Thomas Filleron**, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; **Benjamin Besse** and **Jordi Remon-Masip**, Institute Gustave Roussy, Villejuif; **Gérard Zalcman**, University Hospital Bichat, Paris; **Isabelle Monnet**, Centre Hospitalier Intercommunal de Creteil, Creteil; **Florian Cabillic**, Université de Rennes 1, Rennes, France; **Juergen Wolf** and **Sebastian Michels**, Center for Integrated Oncology, Cologne; **Georg Pall**, Fachkliniken Wangen, Wangen Im Allgäu; **Arne Warth**, Heidelberg University Hospital; **Thomas Muley**, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; **David P. Carbone** and **Dwight Owen**, Ohio State University Comprehensive Cancer Center, Columbus; **Vamsidhar Velcheti**, Cleveland Clinic, Pepper Pike, OH; **Ross Camidge** and **Vignhesh Narayanan**, University of Colorado, Denver; **Robert C. Doebele**, University of Colorado, Aurora, CO; **Pasi A. Janne** and **Mark M. Awad**, Dana-Farber Cancer Institute, Boston, MA; **Daniel D. Karp**, The University of Texas MD Anderson Cancer Center, Houston, TX; **Heather A. Wakelee** and **Joel W. Neal**, Stanford University, Stanford; **Sai-Hong Ignatius Ou**, University of California, Irvine, Orange; **David R. Gandara** and **Jonathan W. Riess**, University of California, Davis Cancer Center, Sacramento, CA; **Alexander Drilon**, Memorial Sloan Kettering Cancer Center, New York, NY; **Nir Peled**, Davidoff Cancer Center, Petach Tiqwa, Israël; **Chul-Cho Byoung**, Yonsei Cancer Center, Seoul, Republic of Korea; **Michael Van Den Heuvel**, Netherlands Cancer Institute, Amsterdam, the Netherlands; **Tony S.K. Mok**, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; **James C.H. Yang** and **Jin-Yuan Shih**, National Taiwan University Hospital, Taipei, Republic of China; **Sanjay Popat**, Royal Marsden Hospital, London, United Kingdom; and **Rafael Rosell** and **Niki Karachaliou**, Catalan Institute of Oncology, Barcelona, Spain.

Support

Data management and statistical analysis was supported by the University Hospital of Toulouse (France). This study was not funded by industry or any other third party.

Prior Presentation

Presented at the 2016 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2016.



AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Targeting *RET* in Patients With *RET*-Rearranged Lung Cancers: Results From the Global, Multicenter *RET* Registry

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifu.

Oliver Gautschi

No relationship to disclose

Julie Milia

No relationship to disclose

Thomas Filleron

No relationship to disclose

Juergen Wolf

Honoraria: AstraZeneca, Bristol-Myers Squibb, Clovis, Eli Lilly, MSD, Novartis, Pfizer, Roche

Consulting or Advisory Role: AstraZeneca, Bristol-Myers Squibb, Clovis, Eli Lilly, MSD, Novartis, Pfizer, Roche

Research Funding: Bristol-Myers Squibb (Inst), MSD (Inst), Novartis (Inst), Pfizer (Inst)

Travel, Accommodations, Expenses: Bristol-Myers Squibb, MSD, Novartis, Pfizer, Roche

David P. Carbone

Consulting or Advisory Role: Merck Sharp & Dohme, Janssen Pharmaceuticals, Genentech, Celgene, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Stem CentRx

Dwight Owen

No relationship to disclose

Ross Camidge

Travel, Accommodations, Expenses: Pfizer

Vignesh Narayanan

No relationship to disclose

Robert C. Doebele

Honoraria: Pfizer, Clovis Oncology, AstraZeneca, ARIAD Pharmaceuticals, Guardant Health

Consulting or Advisory Role: Loxo Oncology, Pfizer, Trovogene, ARIAD Pharmaceuticals

Research Funding: Mirati Therapeutics, Abbott Molecular, Loxo Oncology, Ignyta, Threshold Pharmaceuticals

Patents, Royalties, Other Intellectual Property: Licensing fees from Abbott Molecular for Patent PCT/US2013/057495, licensing fees for biologic material from Blueprint Medicines (Inst), licensing fees for biologic material from Chugai (Inst), licensing fees for biologic material from Ariad (Inst), licensing Fees for biologic materials from GVKbio, licensing fees for biologic materials from Loxo Oncology (Inst)

Travel, Accommodations, Expenses: Ignyta, ARIAD Pharmaceuticals, Guardant Health

Benjamin Besse

Research Funding: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Pfizer, Genentech, BiPar, Sanofi, Clovis Oncology, GlaxoSmithKline, Servier, Eos, Onxeo, OncoMed, Inivata, Ose Pharma

Jordi Remon-Masip

Consulting or Advisory Role: Ose Pharma

Pasi A. Janne

Stock or Other Ownership: Gatekeeper Pharmaceuticals

Consulting or Advisory Role: AstraZeneca, Boehringer Ingelheim, Pfizer, Genentech, ARIAD Pharmaceuticals, Ignyta, Loxo Oncology, Chugai Pharma

Research Funding: AstraZeneca, Astellas Pharma, Puma Biotechnology, Daiichi Sankyo

Patents, Royalties, Other Intellectual Property: DFCI-owned EGFR mutation patent licensed to Laboratory Corp (Inst)

Mark M. Awad

Consulting or Advisory Role: Genentech, Merck, Pfizer, Boehringer Ingelheim, Abbvie, AstraZeneca, MedImmune, Clovis Oncology, Nektar, Bristol-Myers Squibb

Nir Peled

Honoraria: Novartis, Pfizer, MSD Oncology, Eli Lilly, Roche, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb

Consulting or Advisory Role: Roche, Bristol-Myers Squibb, AstraZeneca, MSD Oncology, Eli Lilly, Boehringer Ingelheim

Chul-Cho Byoung

Honoraria: AstraZeneca, Roche, MSD, Bristol-Myers Squibb, Boehringer Ingelheim, Novartis

Consulting or Advisory Role: AstraZeneca, Roche, MSD, Bristol-Myers Squibb, Boehringer Ingelheim, Novartis

Speakers' Bureau: AstraZeneca, Boehringer Ingelheim, Novartis

Daniel D. Karp

No relationship to disclose

Michel Van Den Heuvel

No relationship to disclose

Heather A. Wakelee

Honoraria: Peregrine Pharmaceuticals, ACEA Biosciences, Helsinn Therapeutics, Pfizer

Consulting or Advisory Role: Peregrine Pharmaceuticals, Helsinn Therapeutics, ACEA Biosciences, Pfizer

Research Funding: Genentech (Inst), Pfizer (Inst), Eli Lilly (Inst), Celgene (Inst), AstraZeneca (Inst), MedImmune (Inst), Exelixis (Inst), Novartis (Inst), Regeneron (Inst), Clovis Oncology (Inst), Xcovery (Inst), Bristol-Myers Squibb (Inst), Gilead Sciences (Inst), Pharmacyclics (Inst), ACEA Biosciences (Inst)

Travel, Accommodations, Expenses: Clovis Oncology, Novartis, ACEA Biosciences, Pfizer, Genentech

Joel W. Neal

Consulting or Advisory Role: Clovis Oncology, CARET, Nektar, Boehringer Ingelheim, ARMO BioSciences, ARIAD Pharmaceuticals, Eli Lilly

Research Funding: Genentech, Merck, ArQule, Novartis, Exelixis, Boehringer Ingelheim, Nektar, ARIAD Pharmaceuticals

Tony S.K. Mok

Leadership: Sanomics

Stock or Other Ownership: Sanomics

Honoraria: AstraZeneca, Genentech, Eli Lilly, Merck Serono, Bristol-Myers Squibb, Boehringer Ingelheim, Novartis, Clovis Oncology, Amgen, Janssen Pharmaceuticals, Aveo, Biodesix, Prime Oncology, ACEA Biosciences, Vertex, SFJ Pharmaceuticals Group, Merck Sharp & Dohme, GlaxoSmithKline, Biomarin, Pfizer, Oncogenex, PeerVoice, Celgene

Consulting or Advisory Role: AstraZeneca, Genentech, Eli Lilly, Merck Serono, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Novartis, Clovis Oncology, Amgen, Janssen Pharmaceuticals, Biomarin, Aveo, Bodesix, Vertex, SFJ Pharmaceuticals Group, ACEA Biosciences, Merck Sharp & Dohme, geneDecode, Oncogenex, Celgene

Speakers' Bureau: AstraZeneca, Eli Lilly, Boehringer Ingelheim, Pfizer, Amgen, Genentech, Merck Sharp & Dohme, Janssen Pharmaceuticals, Clovis Oncology, GlaxoSmithKline, Novartis, Bristol-Myers Squibb, Prime Oncology

Research Funding: AstraZeneca (Inst), Boehringer Ingelheim (Inst), Pfizer (Inst), Novartis (Inst), SFJ Pharmaceuticals Group (Inst), Roche (Inst), Merck Sharp & Dohme (Inst), Clovis Oncology (Inst), Bristol-Myers Squibb (Inst)

Travel, Accommodations, Expenses: AstraZeneca, Roche, Eli Lilly, Boehringer Ingelheim, Merck Serono, Pfizer, Amgen, Novartis

James C.H. Yang

Honoraria: Boehringer Ingelheim, Roche, Chugai Pharma, MSD, AstraZeneca, Novartis

Consulting or Advisory Role: Boehringer Ingelheim, Novartis, AstraZeneca, Genentech, Clovis Oncology, Eli Lilly, MSD Oncology, Merck Serono, Celgene, Astellas Pharma, Bayer, Pfizer, Ono Pharmaceutical, Bristol-Myers Squibb, Boehringer Ingelheim (Inst), AstraZeneca (Inst), Yuhon

Sai-Hong Ignatius Ou

Honoraria: Novartis, AstraZeneca, Genentech, Pfizer

Consulting or Advisory Role: ARIAD Pharmaceuticals, Novartis, Genentech

Speakers' Bureau: AstraZeneca, Genentech

Research Funding: AstraZeneca (Inst), ARIAD Pharmaceuticals (Inst), Pfizer (Inst), Roche (Inst), Novartis (Inst)

Georg Pall

Honoraria: Pfizer

Consulting or Advisory Role: Pfizer

Patrizia Froesch

Consulting or Advisory Role: Roche, Bristol-Myers Squibb

G rard Zalcman

Honoraria: Pfizer, Roche, Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim

Consulting or Advisory Role: Bristol-Myers Squibb, Roche, Pfizer

Research Funding: Roche (Inst), Bristol-Myers Squibb (Inst)

Travel, Accommodations, Expenses: Roche, Bristol-Myers Squibb, Pfizer, AstraZeneca

David R. Gandara

Honoraria: AstraZeneca, Vertex, Celgene, Bristol-Myers Squibb, Eli Lilly, Synta, Merck, Novartis, EMD Serono, Roche

Consulting or Advisory Role: Novartis, Celgene, Boehringer Ingelheim, AstraZeneca, Genentech, Merck, Pfizer, Response Genetics, Eli Lilly, ARIAD Pharmaceuticals, Clovis Oncology, Guardant Health, Mirati Therapeutics, Bayer, Synta, Trovogene, Liquid Genomics, Peregrine Pharmaceuticals, Roche, Vertex

Research Funding: Bristol-Myers Squibb (Inst), Genentech (Inst), Eli Lilly (Inst), Merck (Inst), Novartis (Inst), AstraZeneca (Inst), MedImmune (Inst), Clovis Oncology (Inst), Johnson & Johnson (Inst)

Jonathan W. Riess

Honoraria: Genentech

Consulting or Advisory Role: Celgene, ARIAD Pharmaceuticals, Clovis Oncology, Medtronic

Research Funding: Onconova Therapeutics, Millennium Pharmaceuticals (Inst), Novartis (Inst), Merck (Inst)

Travel, Accommodations, Expenses: Genentech, Celgene, Astra Zeneca

Vamsidhar Velcheti

No relationship to disclose

Kristin Zeidler

No relationship to disclose

Joachim Diebold

No relationship to disclose

Martin Fr h

No relationship to disclose

Sebastian Michels

Honoraria: Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim

Consulting or Advisory Role: Boehringer Ingelheim, Pfizer

Research Funding: Pfizer (Inst), Novartis (Inst), Bristol-Myers Squibb (Inst)

Travel, Accommodations, Expenses: Novartis

Isabelle Monnet

No relationship to disclose

Sanjay Popat

Honoraria: Boehringer Ingelheim, Novartis, Eli Lilly, AstraZeneca

Consulting or Advisory Role: Boehringer Ingelheim, Novartis, Eli Lilly, AstraZeneca, Boehringer Ingelheim (Inst), Roche

Travel, Accommodations, Expenses: Boehringer Ingelheim, MSD, Bristol-Myers Squibb, Pfizer

Rafael Rosell

No relationship to disclose

Niki Karachaliou

No relationship to disclose

Sacha I. Rothschild

Consulting or Advisory Role: Bristol-Myers Squibb (Inst), AstraZeneca (Inst), Eli Lilly (Inst), Boehringer Ingelheim (Inst), Eisai (Inst), Roche (Inst), Novartis (Inst), Merck Serono (Inst), MSD Oncology (Inst), Astellas Pharma (Inst), Bayer (Inst), Pfizer (Inst)

Research Funding: Boehringer Ingelheim (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst)

Travel, Accommodations, Expenses: Roche, Eli Lilly, Bristol-Myers Squibb, Amgen

Jin-Yuan Shih

Honoraria: AstraZeneca, Roche, Eli Lilly, Boehringer Ingelheim, Pfizer, MSD Oncology

Arne Warth

Consulting or Advisory Role: AstraZeneca, Roche, Novartis

Thomas Muley

Honoraria: Roche

Speakers' Bureau: Roche

Research Funding: Roche (Inst), Chugai Pharma (Inst)

Travel, Accommodations, Expenses: Roche

Florian Cabillic

No relationship to disclose

Julien Mazi res

No relationship to disclose

Alexander Drilon

Honoraria: Ignyta, Exelixis, Genentech, AstraZeneca, Blueprint Medicines, Loxo Oncology, ARIAD Pharmaceuticals

Research Funding: Foundation Medicine

Acknowledgment

We thank all patients for supporting this study.